ALGS Clinical trials

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Published September 03, 2025 at 08:05 PM

(NASDAQ:ALGS) SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany.